GlassScriptPhysician profile
Brian P Riff
NPI 1194969030
$68,309.22
in general payments reported to CMS, 2019-2025
39 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,256 · 2020: $674 · 2021: $909 · 2022: $1,107 · 2023: $1,073 · 2024: $45K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $7,853 · Consulting Fee: $3,821 · Travel and Lodging: $3,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,500.00 |
| Food and Beverage | $7,853.44 |
| Consulting Fee | $3,821.43 |
| Travel and Lodging | $3,187.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $54,041.59 | 2024-2025 | Voquezna |
| Olympus Medical Systems Corporation | $3,000.00 | 2025 | Evis Exera III Duodenovideoscope, Evis Exera II Ultrasound Gastrovideoscope |
| Abbvie INC. | $2,335.50 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Ardelyx, INC. | $1,835.65 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $1,054.47 | 2021-2025 | Endoflip |
| Gilead Sciences, INC. | $944.55 | 2019-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $941.38 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $747.97 | 2019-2025 | |
| Endogastric Solutions, INC | $428.61 | 2019-2023 | Esophyx |
| Janssen Biotech, INC. | $361.91 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $360.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $358.64 | 2019-2024 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $225.99 | 2024-2025 | Zenpep, Vowst |
| Enterra Medical, INC. | $223.58 | 2023-2024 | |
| Madrigal Pharmaceuticals | $217.25 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $181.61 | 2025 | Iqirvo |
| Lilly USA, LLC | $154.76 | 2025 | Omvoh |
| Mirum Pharmaceuticals, INC. | $130.68 | 2025 | Livmarli |
| Boston Scientific Corporation | $125.00 | 2024 | |
| Steris Corporation | $113.82 | 2023 | |
| Intercept Pharmaceuticals, INC. | $110.74 | 2019-2025 | |
| Celgene Corporation | $82.88 | 2021-2024 | Zeposia |
| Shionogi INC | $54.96 | 2019 | |
| Redhill Biopharma INC. | $33.66 | 2024 | Talicia |
| Organon LLC | $31.72 | 2023 | Hadlima |
| Qol Medical, LLC | $30.96 | 2022-2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $21.88 | 2025 | Dupixent |
| Olympus America INC. | $20.28 | 2019 | |
| Vivus LLC | $19.86 | 2025 | Qsymia |
| Nestle Healthcare Nutrition INC. | $18.53 | 2023 | |
| Novo Nordisk INC | $18.30 | 2025 | Wegovy |
| Alfasigma USA, INC. | $17.34 | 2020 | |
| Exact Sciences Corporation | $15.86 | 2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $15.17 | 2023 | Linzess |
| Celltrion USA INC. | $14.59 | 2025 | Vegzelma |
| W. L. Gore & Associates, INC. | $11.41 | 2020 | |
| Intra-Sana Laboratories | $8.00 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Riff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.